SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development

Nicholas Murgolo; Alex G. Therien; Bonnie Howell; Daniel Klein; Kenneth Koeplinger; Linda A. Lieberman; Gregory C. Adam; Jessica Flynn; Philip McKenna; Gokul Swaminathan; Daria J. Hazuda; David B. Olsen

doi:10.1371/journal.ppat.1009225

Loading metrics

Open Access

Review articles synthesize the best available evidence on a topic relevant to the pathogens community.

See all article types »

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development

Nicholas Murgolo ,

* E-mail: nicholas.murgolo@merck.com

Affiliation Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey, United States of America

https://orcid.org/0000-0001-7094-3344

⨯
Alex G. Therien,

Affiliation Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America
⨯
Bonnie Howell,

Affiliation Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America

https://orcid.org/0000-0002-5915-9943

⨯
Daniel Klein,

Affiliation Department of Computational and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, United States of America
⨯
Kenneth Koeplinger,

Affiliation Department of Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania, United States of America

https://orcid.org/0000-0001-5469-4448

⨯
Linda A. Lieberman,

Affiliation Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America
⨯
Gregory C. Adam,

Affiliation Department of Quantitative Biosciences, Merck & Co., Inc., West Point, Pennsylvania, United States of America

https://orcid.org/0000-0002-2155-6927

⨯
Jessica Flynn,

Affiliation Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America

https://orcid.org/0000-0003-4406-0235

⨯
Philip McKenna,

Affiliation Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America
⨯
Gokul Swaminathan,

Affiliation Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America
⨯
Daria J. Hazuda,

Affiliation Discovery Biology & Translational Medicine, Merck & Co., Inc., West Point, Pennsylvania, United States of America
⨯
David B. Olsen

¶‡ Senior author.

Affiliation Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America

https://orcid.org/0000-0001-5521-0206

⨯

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development

Nicholas Murgolo,
Alex G. Therien,
Bonnie Howell,
Daniel Klein,
Kenneth Koeplinger,
Linda A. Lieberman,
Gregory C. Adam,
Jessica Flynn,
Philip McKenna,
Gokul Swaminathan

Published: February 17, 2021
https://doi.org/10.1371/journal.ppat.1009225

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

SARS CoV 2
Is the Subject Area "SARS CoV 2" applicable to this article?

Thanks for your feedback.
COVID 19
Is the Subject Area "COVID 19" applicable to this article?

Thanks for your feedback.
Respiratory infections
Is the Subject Area "Respiratory infections" applicable to this article?

Thanks for your feedback.
Viral entry
Is the Subject Area "Viral entry" applicable to this article?

Thanks for your feedback.
Lung development
Is the Subject Area "Lung development" applicable to this article?

Thanks for your feedback.
SARS coronavirus
Is the Subject Area "SARS coronavirus" applicable to this article?

Thanks for your feedback.
Proteases
Is the Subject Area "Proteases" applicable to this article?

Thanks for your feedback.
Coronaviruses
Is the Subject Area "Coronaviruses" applicable to this article?

Thanks for your feedback.